000304843 001__ 304843
000304843 005__ 20251208155213.0
000304843 0247_ $$2doi$$a10.1093/jnci/djaf201
000304843 0247_ $$2pmid$$apmid:40987470
000304843 0247_ $$2ISSN$$a0027-8874
000304843 0247_ $$2ISSN$$a1460-2105
000304843 0247_ $$2ISSN$$a1475-4029
000304843 0247_ $$2altmetric$$aaltmetric:181632630
000304843 037__ $$aDKFZ-2025-01949
000304843 041__ $$aEnglish
000304843 082__ $$a610
000304843 1001_ $$00000-0002-4888-6037$$aHazelwood, Emma$$b0
000304843 245__ $$aAdiposity distribution and risks of 12 obesity-related cancers: a Mendelian randomization analysis.
000304843 260__ $$aOxford$$bOxford Univ. Press$$c2025
000304843 3367_ $$2DRIVER$$aarticle
000304843 3367_ $$2DataCite$$aOutput Types/Journal article
000304843 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1765205488_2584395
000304843 3367_ $$2BibTeX$$aARTICLE
000304843 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000304843 3367_ $$00$$2EndNote$$aJournal Article
000304843 500__ $$a2025 Dec 1;117(12):2621-2642
000304843 520__ $$aThere is convincing evidence that overall adiposity increases the risks of several cancers. Whether the distribution of adiposity plays a similar role is unclear.We used 2-sample Mendelian randomization (MR) to examine causal relationships of 5 adiposity distribution traits (abdominal subcutaneous adipose tissue (ASAT); visceral adipose tissue (VAT); gluteofemoral adipose tissue (GFAT); liver fat; and pancreas fat) with the risks of 12 obesity-related cancers (endometrial, ovarian, breast, colorectal, pancreas, multiple myeloma, liver, kidney (renal cell), thyroid, gallbladder, esophageal adenocarcinoma, and meningioma).Sample size across all genome-wide association studies (GWAS) ranged from 8407 to 728 896 (median: 57 249). We found evidence that higher genetically predicted ASAT increased the risks of endometrial cancer, liver cancer, and esophageal adenocarcinoma (odds ratios (OR) and 95% confidence intervals (CI) per standard deviation (SD) higher ASAT = 1.79 (1.18 to 2.71), 3.83 (1.39 to 10.53), and 2.34 (1.15 to 4.78), respectively). Conversely, we found evidence that higher genetically predicted GFAT decreased the risks of breast cancer and meningioma (ORs and 95% CIs per SD higher genetically predicted GFAT = 0.77 (0.62 to 0.97) and 0.53 (0.32 to 0.90), respectively). We also found evidence for an effect of higher genetically predicted VAT and liver fat on increased liver cancer risk (ORs and 95% CIs per SD higher genetically predicted adiposity trait = 4.29 (1.41 to 13.07) and 4.09 (2.29 to 7.28), respectively).Our analyses provide novel insights into the relationship between adiposity distribution and cancer risk. These insights highlight the potential importance of adipose tissue distribution alongside maintaining a healthy weight for cancer prevention.
000304843 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000304843 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000304843 7001_ $$00000-0003-1481-6871$$aGoudswaard, Lucy J$$b1
000304843 7001_ $$00000-0001-6262-3447$$aLee, Matthew A$$b2
000304843 7001_ $$aVabistsevits, Marina$$b3
000304843 7001_ $$00000-0001-8798-920X$$aPournaras, Dimitri J$$b4
000304843 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b5$$udkfz
000304843 7001_ $$00000-0003-2225-6675$$aBuchanan, Daniel D$$b6
000304843 7001_ $$00000-0001-8656-7822$$aGruber, Stephen B$$b7
000304843 7001_ $$00000-0002-9795-1528$$aGsur, Andrea$$b8
000304843 7001_ $$aLi, Li$$b9
000304843 7001_ $$00000-0002-8277-539X$$aVodickova, Ludmila$$b10
000304843 7001_ $$aGrant, Robert C$$b11
000304843 7001_ $$00009-0003-9740-9696$$aSamadder, N Jewel$$b12
000304843 7001_ $$aTimpson, Nicholas J$$b13
000304843 7001_ $$00000-0001-5472-6761$$aGunter, Marc J$$b14
000304843 7001_ $$aSchuster-Böckler, Benjamin$$b15
000304843 7001_ $$00000-0003-4371-0873$$aYarmolinsky, James$$b16
000304843 7001_ $$00000-0002-7918-2040$$aRichardson, Tom G$$b17
000304843 7001_ $$00000-0001-8648-4998$$aFreisling, Heinz$$b18
000304843 7001_ $$aMurphy, Neil$$b19
000304843 7001_ $$00000-0002-8917-7384$$aVincent, Emma E$$b20
000304843 773__ $$0PERI:(DE-600)2129984-5$$a10.1093/jnci/djaf201$$gp. djaf201$$n12$$p2621-2642$$tJNCI cancer spectrum$$v117$$x0027-8874$$y2025
000304843 909CO $$ooai:inrepo02.dkfz.de:304843$$pVDB
000304843 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000304843 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000304843 9141_ $$y2025
000304843 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJNCI-J NATL CANCER I : 2022$$d2023-10-25
000304843 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-25
000304843 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-25
000304843 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-10-25
000304843 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-10-25
000304843 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-10-25
000304843 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-25
000304843 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-25
000304843 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-10-25
000304843 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-25
000304843 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-10-25
000304843 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2023-10-25
000304843 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-10-25
000304843 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-10-25
000304843 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bJNCI-J NATL CANCER I : 2022$$d2023-10-25
000304843 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie der Krebsfrüherkennung$$x0
000304843 9201_ $$0I:(DE-He78)C120-20160331$$kC120$$lPrimäre Krebsprävention$$x1
000304843 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x2
000304843 980__ $$ajournal
000304843 980__ $$aVDB
000304843 980__ $$aI:(DE-He78)C070-20160331
000304843 980__ $$aI:(DE-He78)C120-20160331
000304843 980__ $$aI:(DE-He78)HD01-20160331
000304843 980__ $$aUNRESTRICTED